BiomX to Present at Upcoming September Investor Conferences

NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences.

Event: HC Wainwright 22nd Annual Global Investments Conference

Date: Monday, Sept. 14, 2020

Time: 12:30 p.m. EDT

Webcast link: https://wsw.com/admin/link/zoom.aspx?423748614

Event: Cantor 2020 Virtual Global Healthcare Conference

Date: Wednesday, Sept. 16, 2020

Time: 11:20 a.m. EDT

Webcast link: https://www.webcaster4.com/Webcast/Page/2495/37313

Webcasts will also be available in the Events section of the BiomX website at www.biomx.com. Archived replays will be accessible following each event. (Read more…)

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Safe Harbor Language

This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses its collaboration with Boehringer Ingelheim and the potential thereof, the potential of the XMarker to produce meaningful and useful information, the potential of its product candidates, the increasing importance of microbiome composition and BiomX’s leading position, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and additional disclosures BiomX makes in its filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

Contacts

Noel Kurdi, BiomX

VP Investor Relations and Strategy

(646) 241-4400

[email protected]

Media:

Rich Allan, Solebury Trout

(646) 378-2958

[email protected]